Nuvalent Total Liabilities 2021-2025 | NUVL

Nuvalent total liabilities for the quarter ending March 31, 2025 were $0.095B, a 183.45% increase year-over-year.

  • Nuvalent total liabilities for 2024 were $0.072B, a 126.13% increase from 2023.
  • Nuvalent total liabilities for 2023 were $0.032B, a 63.35% increase from 2022.
  • Nuvalent total liabilities for 2022 were $0.019B, a 121.7% increase from 2021.

Nuvalent Total Liabilities 2021-2025 | NUVL

  • Nuvalent total liabilities for 2024 were $0.072B, a 126.13% increase from 2023.
  • Nuvalent total liabilities for 2023 were $0.032B, a 63.35% increase from 2022.
  • Nuvalent total liabilities for 2022 were $0.019B, a 121.7% increase from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$225.3B
Amgen (AMGN)$164.8B
Gilead Sciences (GILD)$144.5B
Vertex Pharmaceuticals (VRTX)$120.6B
Bristol Myers Squibb (BMY)$98.6B
CSL (CSLLY)$85.4B
GSK (GSK)$77.5B
Regeneron Pharmaceuticals (REGN)$60.8B
Alnylam Pharmaceuticals (ALNY)$42.9B
Argenex SE (ARGX)$36.2B
BioNTech SE (BNTX)$27.7B
Royalty Pharma (RPRX)$20.6B
Insmed (INSM)$19.7B
Biogen (BIIB)$19.3B
Illumina (ILMN)$17.3B
Genmab (GMAB)$15B
Genmab (GNMSF)$15B
Incyte (INCY)$13.6B
Moderna (MRNA)$13.2B
Exelixis (EXEL)$12.4B
QIAGEN (QGEN)$11.5B
BioMarin Pharmaceutical (BMRN)$11.3B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Ascendis Pharma (ASND)$10.2B
Bio-Techne Corp (TECH)$9.2B
Exact Sciences (EXAS)$9.1B
Verona Pharma American Depositary Share (VRNA)$9B
Blueprint Medicines (BPMC)$8.3B
Legend Biotech (LEGN)$8B
Roivant Sciences (ROIV)$7.9B